The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study-Reference-Cited by-同舟云学术

The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study

Published:2021-03 Issue: Volume:109 Page:80-91
ISSN:0046-8177
Container-title:Human Pathology
language:en
Short-container-title:Human Pathology

Author:

van Weelden Willem Jan^ORCID,Reijnen Casper,Küsters-Vandevelde Heidi V.N.,Bulten Johan,Bult Peter^ORCID,Leung Samuel^ORCID,Visser Nicole C.M.,Santacana Maria,Bronsert Peter,Hirschfeld Marc,Colas Eva,Gil-Moreno Antonio^ORCID,Reques Armando^ORCID,Mancebo Gemma,Huvila Jutta^ORCID,Koskas Martin,Weinberger Vit^ORCID,Bednarikova Marketa,Hausnerova Jitka,Snijders Marc P.L.M.,Matias-Guiu Xavier,Amant Frédéric,Krakstad Camilla,van de Vijver Koen,McAlpine Jessica^ORCID,Pijnenborg Johanna M.A.^ORCID

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference40 articles.

1. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial;Trovik;Eur J Canc,2013

2. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer;Jongen;Gynecol Oncol,2009

3. Progesterone-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms;Conneely;Steroids,2003

4. Normal and malignant human endometrium express immunohistochemically estrogen receptor alpha (ER-alpha), estrogen receptor beta (ER-beta) and progesterone receptor (PR);Mylonas;Anticancer Res,2005

5. The steroid and thyroid hormone receptor superfamily;Evans;Science,1988

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Redefining the Position of Hormonal Therapy in Endometrial Cancer in the Era of Molecular Classification;Journal of Clinical Oncology;2024-01-01

2. The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma;International Journal of Gynecologic Cancer;2023-10-31

3. Pulmonary metastasis of stage I, low-grade endometrioid carcinoma: two case reports and the literature review;Frontiers in Oncology;2023-10-12

4. Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?;International Journal of Gynecologic Cancer;2023-08-27

5. Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification;European Journal of Cancer;2023-06